Partial atlE sequencing (atlE nucleotides 2782 to 3114 [atlE(2782-3114)]) was performed in 41 Staphylococcus epidermidis isolates from prosthetic joint infections (PJIs) and 44 isolates from skin as controls. The atlE(2782-3114) allele 1 (type strain sequence) was significantly more frequent in PJI strains (38/41 versus 29/44 in controls; P = 0.0023). Most PJI strains were positive for mecA, ic...

زمینه و هدف: بیماری کبد چرب غیرالکلی رایج‌ترین کبدی است که در حال پیشرفت بوده بیش از یک‌چهارم مردم جهان را درگیر خود ساخته است. این پژوهشگران معتقدند فعالیت ورزشی استفاده داروهای گیاهی با خواص ضدچربی ضداکسایشی می‌تواند به‌عنوان درمان مکمل، سودمند باشد. بنابراین، هدف پژوهش تعیین آثار هشت هفته تمرین هوازی یا مصرف عرق آرتیشو بر سطوح چربی سرمی آنزیم‌های زنان مبتلا به بود. مواد روش‌ها: بدین‌منظور، 2...

Objective: To characterize the motor performance of newborns in a neonatal unit of tertiary level and compare the results to the values recommended by the Test of Infant Motor Performance (TIMP). Method: Newborns between 34 and 416/7 weeks of corrected gestational age, breathing spontaneously and presenting state of consciousness 4 or 5, according to Brazelton, were included. TIMP was used to...

Meloidogyne incognita eggs or J2 were incubated in test tubes containing sand:peat mix and immersed in a water bath heated to 38, 39, 40, 41, 42, 43, 44 and 45 degrees C for a series of time intervals. Controls were maintained at 22 degrees C. Nematodes surviving or hatching were collected from Baermann trays after three weeks of incubation. Regression analyses between percent survival or egg h...

Inhibition of 5-lipoxygenase by anthralin (1) and 41 derivatives is determined: the acids 38 and 39, the lactones 40-42 and 9-anthrone (8) are the most potent inhibitors, the lactone 41 reaching the efficacy of nordihydroguaiaretic acid (NDGA). The results were correlated with the hydrophilic/lipophilic balance of the test compounds and their clinical efficacy as far as known. There is no corre...

..............................................................................................................7 LIST OF PUBLICATIONS.........................................................................................9 ABBREVIATIONS...................................................................................................10 1. THE IMMUNE SYSTEM .........................................

Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20 3.9 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 7.4 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37 7.2 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 6.8 20 to 24 years . . . . . . . . . . . . . . . . . . . . . . ....

Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28 5.1 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 6.9 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 7.1 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 8.9 20 to 24 years . . . . . . . . . . . . . . . . . . . . . . ....

E C 33 34 35 36 37 38 39 40 41 42 43 44 45 46 Article history: Received 21 May 2008 Received in revised form 1 May 2009 Accepted 1 May 2009 Available online xxxx

28 29 30 31 32 33 34 35 36 37 38 39 40 41 Article history: Received 21 April 2014 Received in revised form 23 October 2014 Accepted 27 January 2015 Available online xxxx